$ARTH
Arch Therapeutics, Inc.

2013 Q3 Form 10-Q Financial Statement

#000114420413046058 Filed on August 14, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2013 Q2 2012 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $450.0K $110.0K
YoY Change 275.0% 1000.0%
% of Gross Profit
Research & Development $43.75K $40.00K
YoY Change 133.33%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $960.0K $494.8K $150.0K
YoY Change 540.0% 260.35% 1400.0%
Operating Profit -$494.8K
YoY Change 260.35%
Interest Expense $19.60K -$40.00K
YoY Change -50.05%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change
Pretax Income -$960.0K -$510.0K -$190.0K
YoY Change 405.26% 183.33% 1800.0%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$960.0K -$514.4K -$190.0K
YoY Change 405.26% 190.87% 1800.0%
Net Earnings / Revenue
Basic Earnings Per Share -$0.06
Diluted Earnings Per Share -$44.92K -$0.06 -$3.046K
COMMON SHARES
Basic Shares Outstanding 59.15M shares 8.549M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q3 2013 Q2 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $560.0K $480.0K $20.00K
YoY Change 2700.0% 2300.0%
Cash & Equivalents $557.3K $476.4K $17.14K
Short-Term Investments
Other Short-Term Assets $20.00K $0.00 $0.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.577M $477.5K $20.45K
YoY Change 7612.37% 2287.45%
LONG-TERM ASSETS
Property, Plant & Equipment $322.00 $61.00 $908.00
YoY Change -64.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.06K $0.00
YoY Change
Total Long-Term Assets $10.38K $61.00 $908.00
YoY Change 1043.61%
TOTAL ASSETS
Total Short-Term Assets $1.577M $477.5K $20.45K
Total Long-Term Assets $10.38K $61.00 $908.00
Total Assets $1.587M $477.6K $21.36K
YoY Change 7333.07% 2287.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $314.8K $307.5K $258.4K
YoY Change 21.8%
Accrued Expenses $140.0K $0.00 $352.8K
YoY Change -60.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $280.0K
YoY Change -100.0%
Long-Term Debt Due $0.00 $0.00 $1.500M
YoY Change -100.0%
Total Short-Term Liabilities $455.6K $419.3K $2.552M
YoY Change -82.15%
LONG-TERM LIABILITIES
Long-Term Debt $940.0K $0.00 $240.0K
YoY Change 291.67%
Other Long-Term Liabilities $0.00 $0.00 $10.00K
YoY Change -100.0%
Total Long-Term Liabilities $944.7K $0.00 $241.4K
YoY Change 291.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $455.6K $419.3K $2.552M
Total Long-Term Liabilities $944.7K $0.00 $241.4K
Total Liabilities $1.400M $419.3K $2.794M
YoY Change -49.88%
SHAREHOLDERS EQUITY
Retained Earnings -$4.632M
YoY Change
Common Stock $60.15K $58.65K $5.645K
YoY Change 965.46% 41.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $187.0K $58.28K -$2.772M
YoY Change
Total Liabilities & Shareholders Equity $1.587M $477.6K $21.36K
YoY Change 7333.07% 2287.76%

Cashflow Statement

Concept 2013 Q3 2013 Q2 2012 Q3
OPERATING ACTIVITIES
Net Income -$960.0K -$514.4K -$190.0K
YoY Change 405.26% 190.87% 1800.0%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change
Cash From Operating Activities -$660.0K -$500.0K -$100.0K
YoY Change 560.0% 257.14%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 750.0K 970.0K 100.0K
YoY Change 650.0% 592.86% 400.0%
NET CHANGE
Cash From Operating Activities -660.0K -500.0K -100.0K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 750.0K 970.0K 100.0K
Net Change In Cash 90.00K 470.0K -0.00000000002910
YoY Change -309237645312000600.0% -100.0%
FREE CASH FLOW
Cash From Operating Activities -$660.0K -$500.0K -$100.0K
Capital Expenditures $0.00
Free Cash Flow -$100.0K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
us-gaap Revenues
Revenues
0 USD
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
307548 USD
CY2012Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
258426 USD
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
118560 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
721565 USD
CY2013Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Depreciation
Depreciation
2589 USD
us-gaap Depreciation
Depreciation
18994 USD
dei Amendment Flag
AmendmentFlag
false
us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
431461 USD
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
451046 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
114885 USD
CY2012Q3 us-gaap Assets Current
AssetsCurrent
20447 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
307548 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
62211 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4768 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-667281 USD
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001537561
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58645212 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58645212 shares
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5645212 shares
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5645212 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1121 USD
CY2012Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3308 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
476369 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17139 USD
CY2013Q2 us-gaap Assets Current
AssetsCurrent
477490 USD
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61 USD
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
908 USD
CY2013Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 USD
CY2012Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1395000 USD
CY2013Q2 us-gaap Assets
Assets
477551 USD
CY2012Q3 us-gaap Assets
Assets
21355 USD
CY2013Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
111719 USD
CY2012Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
49510 USD
CY2013Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0 USD
CY2012Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
116548 USD
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
419267 USD
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2552439 USD
CY2013Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 USD
CY2012Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
235000 USD
CY2013Q2 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
0 USD
CY2012Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
6351 USD
CY2013Q2 us-gaap Liabilities
Liabilities
419267 USD
CY2012Q3 us-gaap Liabilities
Liabilities
2793790 USD
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
ARTH
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59145237 shares
dei Entity Registrant Name
EntityRegistrantName
Arch Therapeutics, Inc.
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
us-gaap Interest Expense
InterestExpense
108384 USD
us-gaap Interest Expense
InterestExpense
114702 USD
us-gaap Interest Expense
InterestExpense
588101 USD
CY2013Q2 us-gaap Other Income
OtherIncome
32 USD
CY2012Q2 us-gaap Other Income
OtherIncome
-290 USD
us-gaap Other Income
OtherIncome
51 USD
CY2013Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-19565 USD
CY2012Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
58646 USD
CY2012Q3 us-gaap Common Stock Value
CommonStockValue
5645 USD
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3669971 USD
CY2012Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0 USD
CY2013Q2 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
3670333 USD
CY2012Q3 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
2778080 USD
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
58284 USD
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
-2772435 USD
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
477551 USD
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21355 USD
CY2013Q2 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
0 USD
CY2012Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
275200 USD
CY2013Q2 arth Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
0 USD
CY2012Q3 arth Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
105000 USD
CY2013Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0 USD
CY2012Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
241351 USD
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
0 USD
CY2012Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
352755 USD
CY2012Q2 us-gaap Revenues
Revenues
0 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
225841 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2857530 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43750 USD
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18750 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62356 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42240 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
710128 USD
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
494796 USD
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
137310 USD
us-gaap Operating Expenses
OperatingExpenses
783921 USD
us-gaap Operating Expenses
OperatingExpenses
268081 USD
us-gaap Operating Expenses
OperatingExpenses
3567658 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-494796 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-137310 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-783921 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-268081 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-3136197 USD
CY2013Q2 us-gaap Interest Expense
InterestExpense
19596 USD
CY2012Q2 us-gaap Interest Expense
InterestExpense
39233 USD
us-gaap Other Income
OtherIncome
174 USD
us-gaap Other Income
OtherIncome
53965 USD
CY2012Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-39523 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-108333 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-114528 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-534136 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-514361 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-176833 USD
us-gaap Net Income Loss
NetIncomeLoss
-892254 USD
us-gaap Net Income Loss
NetIncomeLoss
-382609 USD
us-gaap Net Income Loss
NetIncomeLoss
-3670333 USD
CY2013Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8549322 shares
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5638813 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6613249 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5636618 shares
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
arth Noncash Interest Expense On Notes Payable To Related Party
NoncashInterestExpenseOnNotesPayableToRelatedParty
25599 USD
arth Noncash Interest Expense On Notes Payable To Related Party
NoncashInterestExpenseOnNotesPayableToRelatedParty
27790 USD
arth Noncash Interest Expense On Convertible Notes Payable
NoncashInterestExpenseOnConvertibleNotesPayable
441253 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Depreciation
Depreciation
847 USD
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
2859 USD
arth Noncash Interest Expense On Convertible Notes Payable
NoncashInterestExpenseOnConvertibleNotesPayable
82147 USD
arth Noncash Interest Expense On Convertible Notes Payable
NoncashInterestExpenseOnConvertibleNotesPayable
86532 USD
arth Noncash Interest Expense On Notes Payable To Related Party
NoncashInterestExpenseOnNotesPayableToRelatedParty
142057 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
49122 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
111718 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-151625 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2641288 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19054 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19054 USD
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-373488 USD
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
0 USD
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-373488 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
250000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
135000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1985000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1126512 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
135000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3136712 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
459230 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-16626 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
476369 USD
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36775 USD
CY2006Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
us-gaap Interest Paid
InterestPaid
98288 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Interest Paid
InterestPaid
98288 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2187 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3955 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1121 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20149 USD
arth Proceeds From Common Stock Issued In Merger
ProceedsFromCommonStockIssuedInMerger
1250000 USD
arth Proceeds From Common Stock Issued In Merger
ProceedsFromCommonStockIssuedInMerger
0 USD
arth Proceeds From Common Stock Issued In Merger
ProceedsFromCommonStockIssuedInMerger
1250000 USD
arth Issuance Of Common Stock For Services
IssuanceOfCommonStockForServices
0 USD
arth Issuance Of Common Stock For Services
IssuanceOfCommonStockForServices
0 USD
arth Issuance Of Common Stock For Services
IssuanceOfCommonStockForServices
253 USD
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
0 USD
us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
8342 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
275200 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
105000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u><u>Use of Estimates</u></u></div> </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> For a complete summary of our significant accounting policies, refer to Note 2 of our audited financial statements for the fiscal year ended September 30, 2012 <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">in the company&#8217;s Annual Report on Form 10-K filed with the SEC on December 31, 2012 and in the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 26, 2013.</font> There have been no material changes to our significant accounting policies during the nine months ended June 30, 2013.</div> </div>
CY2013Q2 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
14645212 shares
CY2013Q1 arth Related Parties Convertible Notes Value Expired
RelatedPartiesConvertibleNotesValueExpired
50000 USD
CY2013Q2 arth Convertible Preferred Stock Value Upon Closing Of Preferred Equity Financing
ConvertiblePreferredStockValueUponClosingOfPreferredEquityFinancing
1000000 USD
arth Percentage Of Principle Balance Of Notes On Conversion Price Of Notes
PercentageOfPrincipleBalanceOfNotesOnConversionPriceOfNotes
0.2 pure
CY2013Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
250000 USD
CY2013Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1880000 USD
CY2013Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2000000 USD
CY2013Q2 arth Unit Issued Price Per Share
UnitIssuedPricePerShare
0.50
CY2013Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
0.75
arth Proceeds From Investors In Contemplation Of Merger
ProceedsFromInvestorsInContemplationOfMerger
1250000 USD

Files In Submission

Name View Source Status
0001144204-13-046058-index-headers.html Edgar Link pending
0001144204-13-046058-index.html Edgar Link pending
0001144204-13-046058.txt Edgar Link pending
0001144204-13-046058-xbrl.zip Edgar Link pending
arth-20130630.xml Edgar Link completed
arth-20130630.xsd Edgar Link pending
arth-20130630_cal.xml Edgar Link unprocessable
arth-20130630_def.xml Edgar Link unprocessable
arth-20130630_lab.xml Edgar Link unprocessable
arth-20130630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
v351704_10q.htm Edgar Link pending
v351704_ex10-11.htm Edgar Link pending
v351704_ex10-13.htm Edgar Link pending
v351704_ex10-14.htm Edgar Link pending
v351704_ex10-15.htm Edgar Link pending
v351704_ex31-1.htm Edgar Link pending
v351704_ex31-2.htm Edgar Link pending
v351704_ex32-1.htm Edgar Link pending